Financial Results and Business Update for the Quarter Ended December 31, 2025 February 6, 2026 Disclaimer This presentation is intended for the investor community only; it is not intended to promote the product candidates referenced herein or otherwise influence healthcare prescribing decisions. For investor audiences only 2 Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materi ...

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is facing a lawsuit for alleged violations of securities laws, which may impact its financial standing and investor confidence [1] Group 1 - The lawsuit has been initiated by the DJS Law Group, indicating potential legal challenges for the company [1] - The allegations pertain to securities law violations, which could lead to significant financial repercussions for Ultragenyx [1] - Investors are encouraged to discuss their rights in light of the ongoing legal situation [1]

Core Viewpoint - Biogen's stock is rising despite a significant decline in multiple sclerosis revenue and ongoing challenges within its drug portfolio [1] Group 1: Financial Performance - Biogen reported fourth-quarter adjusted earnings and revenue that exceeded analysts' expectations [1] Group 2: Market Reaction - Investors are focusing on the positive earnings report while overlooking the declining sales and poor performance of most of Biogen's drug portfolio in the fourth quarter [1]

Group 1 - Shares in the Danish drugmaker have significantly declined this week due to a weak sales outlook [1] - The decline is further exacerbated by the launch of a Wegovy knockoff [1]

Core Viewpoint - Pfizer Inc. has received Priority Review from the U.S. FDA for its supplemental Biologics License Application for HYMPAVZI® (marstacimab), aiming to expand its indication for treating hemophilia A or B patients aged 6 years and older with inhibitors, as well as pediatric patients aged 6 to 11 with hemophilia A or B without inhibitors [1] Group 1 - The FDA has accepted Pfizer's supplemental Biologics License Application for HYMPAVZI® [1] - The application seeks to expand the treatment indication to include hemophilia A or B patients aged 6 years and older with inhibitors [1] - The application also targets pediatric patients aged 6 to 11 with hemophilia A or B without inhibitors [1]

Core Viewpoint - Hims & Hers faces legal action from Novo Nordisk after announcing plans to launch a cheaper version of Novo's weight loss pill, leading to significant stock price fluctuations [1][2] Group 1: Stock Performance - Hims & Hers stock initially spiked by 15% following the announcement but ended the trading session down 3.8%, reaching a 12-month low [1] - In premarket trading on Friday, shares fell an additional 6.7% after Novo Nordisk labeled the action as "illegal" [1] Group 2: Product Launch Details - Hims plans to introduce a Wegovy-style pill containing semaglutide, priced at $49 for the first month with a subscription, increasing to $99 thereafter [2] - This pricing is significantly lower than Novo Nordisk's starting dose price of $149 on its NovoCare website [2]

Heated competition among pharma companies over obesity drugs is giving some Novo Nordisk investors flashbacks to the 2017 insulin price wars. https://t.co/Q7lziNnFK7 ...

🚨UPDATE: WHITE HOUSE LAUNCHES TRUMPRX DRUG PRICING PORTALAccording to the WSJ, TrumpRx drug-pricing portal, launched Thursday evening, offering cash-pay discounts on 43 brand-name drugs from five manufacturers: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.Drugs from 11 additional manufacturers will be added in coming months.BSCN (@BSCNews):🚨NEW: TRUMP ADMINISTRATION TO LAUNCH TRUMPRX DRUG PRICING PORTAL TONIGHT?TrumpRx is expected to launch Tonight, according @Axios.The direct-to-consumer pl ...

Group 1 - Biogen forecasts 2026 profit exceeding Wall Street estimates, driven by demand for newer medicines and its Alzheimer's treatment Leqembi [1] - The company faces competition as older multiple sclerosis drugs encounter pressure from cheaper alternatives [1]

Biogen forecasts 2026 profit above Wall Street’s expectations, signaling that steep cost-cutting measures are cushioning the impact of shrinking sales from its multiple sclerosis franchise https://t.co/6BLzI5OGNs ...